ArticleCureus2025
An Unexpected Manifestation of Non-islet Cell Tumor Hypoglycemia in Pancreatic Ductal Adenocarcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy accounting for more than 90% of pancreatic cancer cases and is rarely associated with paraneoplastic syndromes. Non-islet cell tumor hypoglycemia (NICTH), typically mediated by insulin-like growth factor 2 (IGF-2), is well-described in mesenchymal tumors and hepatocellular carcinoma but has not been documented in PDAC. We report an 81-year-old man with stage IV PDAC who presented with profound hypoglycemia (glucose 32 mg/dL) in the absence of diabetes or hypoglycemic agents. Despite repeated dextrose infusions, his hypoglycemia persisted, necessitating intensive care unit (ICU) admission. Workup excluded insulinoma, autoimmune hypoglycemia, and adrenal insufficiency. An elevated IGF-2/IGF-1 ratio (457/7) was diagnostic for IGF-2-mediated hypoglycemia. The patient's glucose stabilized with total parenteral nutrition, but he succumbed shortly thereafter to cancer-related complications. This is the first documented case of IGF-2-mediated NICTH in PDAC, underscoring the need to consider paraneoplastic hypoglycemia in atypical presentations of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.